Executive Director of Clock Foundation, CEO & CTO of Intervene Immune

Robert (Bobby) Brooke obtained his MS in Biomedical Engineering from UCLA in 2005.  After graduating, Mr. Brooke worked in healthcare finance with an investment firm in Westwood before starting a career as a biotech entrepreneur.  He has founded multiple companies including an immunotherapy company now known as Iovance Biotherapeutics and a drug developer named Vitality Biopharma.  Currently he is the CEO & CTO of Intervene Immune, which is focused on the prevention or reversal of age-related immune system decline, while also serving as Executive Director of the Epigenetic Clock Development Foundation (Clock Foundation), which is a non-profit and spin-out of UCLA.  

In 2019, Intervene Immune published clinical trial results with UCLA and Stanford collaborators demonstrating rejuvenation of the aged immune system, and also the first ever reversal of epigenetic aging, which is a highly accurate molecular biomarker of aging.  This work led to the expansion of the study into the larger TRIIM-X trial (now ongoing), and also formation of the Clock Foundation, a spin-out of UCLA and lab of Prof. Steve Horvath that is enabling more widespread and rigorous use of epigenetic clocks for aging and longevity studies.  In its first three years of operations, the Clock Foundation has conducted over 300 epigenetic clock studies. These include numerous preclinical and clinical studies in collaboration with researchers in the aging and longevity field at biotech companies and universities.